MetaCap

Evommune (EVMN) vs Fulcrum Therapeutics (FULC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evommune (EVMN) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 62.4% versus a loss of 67.3%. Evommune is the larger company by market cap ($291.1 million vs $281.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVMN-62.37%FULC-67.32%
+76%-2%-80%
Nov 21, 20251 yearNov 20, 2026
EVMN-61.76%FULC-51.64%
+79%-0%-79%
Nov 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVMN versus FULC key metrics
MetricEVMNFULC
Share price$7.04$3.69
Market cap$291.10M$281.85M
1-day change-2.76%-0.54%
YTD return-58.88%-67.37%
1-year return-62.37%-67.32%
5-year return—-75.50%
EPS (TTM)$-3.83$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.00M$0
Revenue growth (YoY)+85.71%-100.00%
Net income (latest FY)$-68.87M$-74.88M
Operating margin-623.62%—
Net margin-529.77%—
52-week high$33.20$15.74
52-week low$4.94$2.83
Distance from 52-week high-78.80%-76.56%
Analyst consensusbuyhold
Avg. price target upside+210.94%-0.54%
Average volume841.65K1.37M
Shares outstanding41.35M76.38M
Employees4855
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Evommune grew revenue faster in its latest fiscal year (+85.71% vs -100.00%).

About Evommune

EVMN stock →

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Fulcrum Therapeutics

FULC stock →

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

EVMN vs FULC FAQ

Which is bigger, Evommune or Fulcrum Therapeutics?

Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $281.85M for Fulcrum Therapeutics (FULC).

Which stock has performed better over the past year, EVMN or FULC?

EVMN returned -62.37% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.

Are Evommune and Fulcrum Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons